Stocks to Sell

Stocks can plunge for any number of reasons — investors may need to raise cash for large milestone purchases, or algorithms could be triggered by stop losses which create massive selloffs. Whatever the case, InvestorPlace’s journalists weed out the markets’ losers, keeping you informed of which stocks to cash out of before they come crashing down.

Weak Fundamentals Prove There Is No Reason to Buy Bionano Genomics

By Stavros Georgiadis, CFA, InvestorPlace Contributor
Bionano Genomics is risky and its valuation does not justify its price. There is no compelling argument for a buy in BNGO stock.

If You Bet on Workhorse, You’re Walking on Your Own

By Josh Enomoto, InvestorPlace Contributor
WKHS stock may have been a high-potential trade but without the USPS contract, it might meander aimlessly for a while.

Krispy Kreme Stock Should Drop 40% To $9.65 Before It Looks Reasonable

By Mark R. Hake, CFA
Krispy Kreme paid off a significant chunk of debt by going public, which we can use to calculate the actual value of DNUT stock.

Blackberry’s Time Has Passed. Stay Away From BB Stock.

By Joel Baglole, InvestorPlace Contributor
The one-time giant of the tech world likes to say it is more than a meme stock, but its finances and outlook say otherwise. Avoid BB stock.

7 Popular China Stocks to Avoid Until Further Notice

By Josh Enomoto, InvestorPlace Contributor
While China stocks have performed well over the last several years, recent headwinds suggest caution is in order.

AMC Stock Faces a Day of Reckoning as Its Debt Load Multiplies

By Will Ashworth, InvestorPlace Contributor
AMC has $11.05 billion in total debt. Could it pass a stress test? That’s an answer investors ought to get before buying AMC stock. 

Ocugen Likely Can’t Get a Boost From the FDA Until 2023

By Larry Ramer, InvestorPlace Contributor
It would likely take until mid-2023 for the FDA to approve Covaxin. By that time, the shot could be obsolete. Sell OCGN stock.

Clover Health Hasn’t Lived Up to Its Billing as a Healthcare Disruptor

By Muslim Farooque, InvestorPlace Contributor
CLOV stock has no competitive moat at this point, as its software has failed to garner traction among healthcare providers.

It’s Holding Up Now, But Gamestop Stock Could Still Tumble

By Thomas Niel, InvestorPlace Contributor
GME stock has been resilient compared to other Reddit plays, but don't take that to mean it's immune from future declines.

Without a Solid Business Plan, GameStop Isn’t Worth It

By Stavros Georgiadis, CFA, InvestorPlace Contributor
GME stock might be down from its earlier highs, but don't think of this as a discount; the company doesn't have a bright future.

Fisker Stock Would Look a Whole Lot Better With Less Short Interest

By Chris Markoch, InvestorPlace Contributor
FSR stock is trading at about 20% of its normal volume. This makes now a good time to reflect on whether Fisker will be disruptive or be disrupted.  

Clover Health Is Either Cursed or Unlucky, but It’s Not a Buy Now

By Joel Baglole, InvestorPlace Contributor
Is healthcare insurer Clover Health Investments more than a meme stock? This is the question that both professional and retail investors are trying to answer after CLOV stock was targeted in late May by the meme stock crowd that congregates on the WallStreetBets Reddit forum. Clover Health has to convince investors that it is more than a flash in the pan meme stock and that its shares are worthy of sustained gains.

GameStop Is Still Overvalued Despite More Positive Catalysts

By Larry Ramer, InvestorPlace Contributor
Netflix's entrance into the vide-game sector could help GameStop, but the valuation of GME stock is still far too high.

Long-Term Investors Should Skip AMC Stock

By Tezcan Gecgil, InvestorPlace Contributor
AMC stock has certainly had an impressive several months, but a real recovery for AMC is unlikely due to streaming and Covid-19.

Mind Medicine Has More Obstacles Than Opportunities

By Muslim Farooque, InvestorPlace Contributor
MNMD stock could revolutionize mental healthcare with its novel therapeutics, but there are currently too many risks with its business.

Forget the Optimism, Harley Davidson Is a Flawed Stock

By Steve Booyens, CFA
Optimism in HOG stock doesn't make sense, as the business is suffering from rebranding pressure and inefficient operational processes.

Avoid Unprofitable Clover Health For the Forseeable Future

By Mark R. Hake, CFA
Clover Health will not be profitable anytime soon, so stay away. CLOV stock is not worth more than $7.86 at best, or 4% below today’s price at 3 times forward sales.

7 Stocks to Avoid… Unless You Like Losing Money

By Joel Baglole, InvestorPlace Contributor
Keeping up with market shifts has been difficult, but there are some names that investors should avoid at all costs right now as they are likely to continue falling over the short and medium term.

Opendoor Technologies Is Vulnerable to the Housing Market’s Double-Edged Sword

By Josh Enomoto, InvestorPlace Contributor
While the underlying technology behind OPEN stock is intriguing, the reality is that the housing market may not cooperate.
Load More Articles